Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates

Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates

The Clinical Laboratory Standards Institute lowered the fluoroquinolone minimum inhibitory concentration (MIC) susceptibility breakpoints for <i>Enterobacteriaceae</i> and glucose non-fermenting Gram-negative bacilli in January 2019. This retrospective cohort study describes the impact o...

Full description

Bibliographic Details
Main Authors:	Stephanie C. Shealy, Matthew M. Brigmon, Julie Ann Justo, P. Brandon Bookstaver, Joseph Kohn, Majdi N. Al-Hasan
Format:	Article
Language:	English
Published:	MDPI AG 2020-04-01
Series:	Antibiotics
Subjects:	sepsis bacteremia ciprofloxacin chemotherapeutics <i>Escherichia coli</i> non-fermenters/<i>Pseudomonas aeruginosa</i>
Online Access:	https://www.mdpi.com/2079-6382/9/4/189

Similar Items

Utility of Combination Antimicrobial Therapy in Adults with Bloodstream Infections due to Enterobacteriaceae and Non-Fermenting Gram-Negative Bacilli Based on In Vitro Analysis at Two Community Hospitals
by: Rachel A. Foster, et al.
Published: (2019-02-01)

Optimization of Empirical Antimicrobial Therapy in <i>Enterobacterales</i> Bloodstream Infection Using the Extended-Spectrum Beta-Lactamase Prediction Score
by: Brian J. Haimerl, et al.
Published: (2023-06-01)

Decoding Genetic Features and Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> Strains Isolated from Bloodstream Infections
by: Tomasz Bogiel, et al.
Published: (2022-08-01)

Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with <i>Pseudomonas aeruginosa</i> Bacteremia
by: Hajime Nakashima, et al.
Published: (2024-02-01)

Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by <em>Enterobacteriaceae</em>
by: Ga Eun Park, et al.
Published: (2021-04-01)

Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance
by: Matteo Bassetti, et al.
Published: (2020-09-01)

Epidemiology of <i>Aeromonas</i> Species Bloodstream Infection in Queensland, Australia: Association with Regional and Climate Zones
by: Holly A. Sinclair, et al.
Published: (2022-12-01)

<i>Pseudomonas aeruginosa</i> Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors
by: Cristina Royo-Cebrecos, et al.
Published: (2022-09-01)

Effects of Enrofloxacin and Ciprofloxacin on Growth and Toxin Production of <i>Microcystis aeruginosa</i>
by: Yu Xia, et al.
Published: (2023-10-01)

Parallel Evolution to Elucidate the Contributions of PA0625 and <i>parE</i> to Ciprofloxacin Sensitivity in <i>Pseudomonas aeruginosa</i>
by: Qi Liu, et al.
Published: (2022-12-01)

Itaconic Acid Increases the Efficacy of Tobramycin against <i>Pseudomonas aeruginosa</i> Biofilms
by: Duy-Khiet Ho, et al.
Published: (2020-07-01)

Design of Phage-Cocktail–Containing Hydrogel for the Treatment of <i>Pseudomonas aeruginosa</i>–Infected Wounds
by: Fatemeh Shafigh Kheljan, et al.
Published: (2023-03-01)

<i>Salmonella</i> Bloodstream Infections
by: Micah J. Worley
Published: (2023-10-01)

Intravenous versus Partial Oral Antibiotic Therapy in the Treatment of Uncomplicated Bloodstream Infection Due to <i>Streptococcus</i> Species
by: Lynn E. Broermann, et al.
Published: (2023-09-01)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
by: Ching-Chi Lee, et al.
Published: (2019-11-01)

Ciprofloxacin-, Cefazolin-, and Methicilin-Soaked Graphene Paper as an Antibacterial Medium Suppressing Cell Growth
by: Barbara Nasiłowska, et al.
Published: (2024-02-01)

ICEs Are the Main Reservoirs of the Ciprofloxacin-Modifying <i>crpP</i> Gene in <i>Pseudomonas aeruginosa</i>
by: João Botelho, et al.
Published: (2020-08-01)

Low-Level Tolerance to Fluoroquinolone Antibiotic Ciprofloxacin in QAC-Adapted Subpopulations of <i>Listeria monocytogenes</i>
by: Divya Kode, et al.
Published: (2021-05-01)

Inhibitory Effect of Thymol on Tympanostomy Tube Biofilms of Methicillin-Resistant <i>Staphylococcus aureus</i> and Ciprofloxacin-Resistant <i>Pseudomonas aeruginosa</i>
by: Eu-Ri Jo, et al.
Published: (2022-09-01)

Influence of Probiotics on the Development of <i>Clostridioides difficile</i> Infection in Patients Receiving Fluoroquinolones
by: Mary E. Sheffield, et al.
Published: (2021-08-01)

Direct Measurement of Performance: A New Era in Antimicrobial Stewardship
by: Majdi N. Al-Hasan, et al.
Published: (2019-08-01)

Molecular Characterization of Fluoroquinolone-Resistant <i>Bartonella bacilliformis</i>
by: Giovanna Mendoza-Mujica, et al.
Published: (2021-07-01)

Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa
by: Lei Zhao, et al.
Published: (2020-08-01)

Hospital-Wide Protocol Significantly Improved Appropriate Management of Patients with <i>Staphylococcus aureus</i> Bloodstream Infection
by: Kawisara Krasaewes, et al.
Published: (2022-06-01)

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
by: Loukas Kakoullis, et al.
Published: (2021-04-01)

Impact of the COVID-19 Pandemic on the Management of <i>Staphylococcus aureus</i> Bloodstream Infections in a Tertiary Care Hospital
by: Christian W. Böing, et al.
Published: (2023-04-01)

Presence of Chromosomal <i>crpP</i>-<i>like</i> Genes Is Not Always Associated with Ciprofloxacin Resistance in <i>Pseudomonas aeruginosa</i> Clinical Isolates Recovered in ICU Patients from Portugal and Spain
by: Marta Hernández-García, et al.
Published: (2021-02-01)

Activity of Antimicrobial Peptides and Ciprofloxacin against <i>Pseudomonas aeruginosa</i> Biofilms
by: Muhammad Yasir, et al.
Published: (2020-08-01)

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an In Vitro Cystic Fibrosis Sputum Model
by: Vaughn D. Craddock, et al.
Published: (2023-06-01)

Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study
by: Lena Herrmann, et al.
Published: (2021-06-01)

Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bloodstream Infection
by: Keh-Sen Liu, et al.
Published: (2021-06-01)

Novel Antimicrobial Agents for Gram-Negative Pathogens
by: Marios Karvouniaris, et al.
Published: (2023-04-01)

The Etiology, Antibiotic Therapy and Outcomes of Bacteremic Skin and Soft-Tissue Infections in Onco-Hematological Patients
by: Valeria Castelli, et al.
Published: (2023-12-01)

Clearance of Gram-Negative Bacterial Pathogens from the Ocular Surface by Predatory Bacteria
by: Eric G. Romanowski, et al.
Published: (2021-07-01)

Empirical fluoroquinolones versus broad-spectrum beta-lactams for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors
by: Majdi N. Al-Hasan, et al.
Published: (2020-09-01)

Factores de riesgo para bacteriemia por Pseudomonas aeruginosa resistente a carbapenémicos adquirida en un hospital colombiano
by: Sandra Liliana Valderrama, et al.
Published: (2016-04-01)

Phylogenomic Investigation of Increasing Fluoroquinolone Resistance among Belgian Cases of Shigellosis between 2013 and 2018 Indicates Both Travel-Related Imports and Domestic Circulation
by: Bert Bogaerts, et al.
Published: (2021-04-01)

Resistance to Fluoroquinolones in <i>Pseudomonas aeruginosa</i> from Human, Animal, Food and Environmental Origin: The Role of <i>CrpP</i> and Mobilizable ICEs
by: María López, et al.
Published: (2022-09-01)

In Vitro Comparison of Antibacterial and Antibiofilm Activities of Selected Fluoroquinolones against <i>Pseudomonas aeruginosa</i> and Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Majed M. Masadeh, et al.
Published: (2019-01-01)

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17
by: Esther Wohlfarth, et al.
Published: (2023-05-01)